CollPlant Biotechnologies Stock Price, News & Analysis (NASDAQ:CLGN) $5.17 -0.18 (-3.36%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$5.15▼$5.4550-Day Range$4.98▼$6.6452-Week Range$4.70▼$13.97Volume2,502 shsAverage VolumeN/AMarket Capitalization$57.34 millionP/E RatioN/ADividend YieldN/APrice Target$16.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media CollPlant Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside226.4% Upside$16.88 Price TargetShort InterestHealthy0.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.11 to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector558th out of 932 stocksSurgical Appliances & Supplies Industry15th out of 17 stocks 3.5 Analyst's Opinion Consensus RatingCollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.88, CollPlant Biotechnologies has a forecasted upside of 226.4% from its current price of $5.17.Amount of Analyst CoverageCollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.23% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently decreased by 15.64%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCollPlant Biotechnologies does not currently pay a dividend.Dividend GrowthCollPlant Biotechnologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLGN. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of CollPlant Biotechnologies is held by insiders.Percentage Held by InstitutionsOnly 4.53% of the stock of CollPlant Biotechnologies is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CollPlant Biotechnologies are expected to decrease in the coming year, from $0.11 to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CollPlant Biotechnologies is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CollPlant Biotechnologies is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCollPlant Biotechnologies has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CollPlant Biotechnologies Stock (NASDAQ:CLGN)CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.Read More CLGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLGN Stock News HeadlinesDecember 2, 2023 | benzinga.comCollPlant Biotechnologies Stock (NASDAQ:CLGN), Analyst Ratings, Price Targets, PredictionsDecember 1, 2023 | finance.yahoo.comCollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Call TranscriptDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 1, 2023 | americanbankingnews.comCollPlant Biotechnologies (NASDAQ:CLGN) Receives "Buy" Rating from HC WainwrightNovember 29, 2023 | benzinga.comRecap: CollPlant Biotechnologies Q3 EarningsNovember 29, 2023 | msn.comCollPlant Biotechnologies Non-GAAP EPS of -$0.35November 29, 2023 | finance.yahoo.comCollPlant Biotechnologies Announces Third Quarter Financial Results for 2023November 9, 2023 | finance.yahoo.comCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATIONDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 3, 2023 | finance.yahoo.comWill CollPlant Biotechnologies (NASDAQ:CLGN) Spend Its Cash Wisely?November 1, 2023 | msn.comCollPlant says patent granted in U.S. for photocurable dermal fillerNovember 1, 2023 | finance.yahoo.comCollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal FillerOctober 5, 2023 | finance.yahoo.comShareholders in CollPlant Biotechnologies (NASDAQ:CLGN) are in the red if they invested three years agoSeptember 21, 2023 | finance.yahoo.comCollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability InitiativeSeptember 5, 2023 | finance.yahoo.comCollPlant to Present at the H.C. Wainwright Annual Growth ConferenceAugust 27, 2023 | finance.yahoo.comResults: CollPlant Biotechnologies Ltd. Beat Earnings Expectations And Analysts Now Have New ForecastsAugust 26, 2023 | finance.yahoo.comInvestors Don't See Light At End Of CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) TunnelAugust 25, 2023 | finance.yahoo.comCollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2023 Earnings Call TranscriptAugust 25, 2023 | markets.businessinsider.comCollplant Holdings (CLGN) Gets a Buy from H.C. WainwrightAugust 24, 2023 | seekingalpha.comCollPlant Biotechnologies Non-GAAP EPS of $0.52, revenue of $10.2M beats by $4.86MAugust 24, 2023 | finance.yahoo.comCollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 MillionAugust 23, 2023 | benzinga.comPreview: CollPlant Biotechnologies's EarningsAugust 9, 2023 | finance.yahoo.comCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATIONJune 26, 2023 | benzinga.comWhy CollPlant Biotechnologies Stock Is Trading HigherMay 27, 2023 | es-us.finanzas.yahoo.comCollPlant Biotechnologies First Quarter 2023 Earnings: Beats ExpectationsMay 25, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Collplant Holdings (CLGN)May 24, 2023 | msn.comCollPlant Biotechnologies: Q1 Earnings InsightsSee More Headlines Receive CLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/24/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLGN CUSIPN/A CIK1631487 Webwww.collplant.com Phone972732325600Fax972-73-232-5602Employees73Year FoundedN/APrice Target and Rating Average Stock Price Target$16.88 High Stock Price Target$22.75 Low Stock Price Target$11.00 Potential Upside/Downside+226.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E Ratio47.00 P/E GrowthN/ANet Income$-16,920,000.00 Net Margins-62.80% Pretax Margin-62.80% Return on Equity-20.61% Return on Assets-17.64% Debt Debt-to-Equity RatioN/A Current Ratio11.85 Quick Ratio11.28 Sales & Book Value Annual Sales$300,000.00 Price / Sales191.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.91 per share Price / Book1.78Miscellaneous Outstanding Shares11,090,000Free Float10,022,000Market Cap$57.34 million OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Yehiel Tal (Age 71)CEO & Director Comp: $865kMr. Eran Rotem CPA (Age 55)Deputy CEO & CFO Comp: $651kProf. Oded Shoseyov (Age 67)Founder & Chief Scientist Comp: $384kMr. Oren Fahimipoor (Age 41)Vice President of Operations Ms. Hadas Dreiher Horowitz (Age 46)Vice President of Human Resources Dr. Elana Gazal (Age 48)Vice President of Research & Development More ExecutivesKey CompetitorsMilestone ScientificNYSE:MLSSEargoNASDAQ:EARReWalk RoboticsNASDAQ:RWLKOceanTech Acquisitions INASDAQ:OTECEnvoy MedicalNASDAQ:COCHView All CompetitorsInstitutional OwnershipPinnacle Associates Ltd.Sold 6,344 shares on 10/24/2023Ownership: 4.313%Villere ST Denis J & Co. LLCBought 7,450 shares on 10/20/2023Ownership: 2.707%View All Institutional Transactions CLGN Stock Analysis - Frequently Asked Questions Should I buy or sell CollPlant Biotechnologies stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLGN shares. View CLGN analyst ratings or view top-rated stocks. What is CollPlant Biotechnologies' stock price target for 2024? 2 brokerages have issued twelve-month target prices for CollPlant Biotechnologies' stock. Their CLGN share price targets range from $11.00 to $22.75. On average, they expect the company's share price to reach $16.88 in the next year. This suggests a possible upside of 226.4% from the stock's current price. View analysts price targets for CLGN or view top-rated stocks among Wall Street analysts. How have CLGN shares performed in 2023? CollPlant Biotechnologies' stock was trading at $8.35 at the beginning of 2023. Since then, CLGN shares have decreased by 38.1% and is now trading at $5.17. View the best growth stocks for 2023 here. Are investors shorting CollPlant Biotechnologies? CollPlant Biotechnologies saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 17,800 shares, a decrease of 15.6% from the October 31st total of 21,100 shares. Based on an average daily trading volume, of 14,600 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.2% of the shares of the company are sold short. View CollPlant Biotechnologies' Short Interest. When is CollPlant Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our CLGN earnings forecast. How were CollPlant Biotechnologies' earnings last quarter? CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) released its earnings results on Thursday, August, 24th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.83. The business had revenue of $10.18 million for the quarter, compared to analysts' expectations of $0.26 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 20.61% and a negative net margin of 62.80%. During the same quarter last year, the firm earned ($0.39) earnings per share. What other stocks do shareholders of CollPlant Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA), Boingo Wireless (WIFI), Allena Pharmaceuticals (ALNA), Advanced Micro Devices (AMD), Energy Transfer (ET), HTG Molecular Diagnostics (HTGM), OPKO Health (OPK), Ovid Therapeutics (OVID) and When did CollPlant Biotechnologies IPO? (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager. Who are CollPlant Biotechnologies' major shareholders? CollPlant Biotechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (4.31%), Villere ST Denis J & Co. LLC (2.71%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of CollPlant Biotechnologies? Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CLGN) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.